Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Foghorn Therapeutics (FHTX) Shares Outstanding (Diluted Average): 2020-2024

Historic Shares Outstanding (Diluted Average) for Foghorn Therapeutics (FHTX) over the last 5 years, with Dec 2024 value amounting to $54.9 million.

  • Foghorn Therapeutics' Shares Outstanding (Diluted Average) rose 0.68% to $63.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $63.0 million, marking a year-over-year increase of 0.68%. This contributed to the annual value of $54.9 million for FY2024, which is 30.79% up from last year.
  • Foghorn Therapeutics' Shares Outstanding (Diluted Average) amounted to $54.9 million in FY2024, which was up 30.79% from $42.0 million recorded in FY2023.
  • In the past 5 years, Foghorn Therapeutics' Shares Outstanding (Diluted Average) registered a high of $54.9 million during FY2024, and its lowest value of $11.0 million during FY2020.
  • In the last 3 years, Foghorn Therapeutics' Shares Outstanding (Diluted Average) had a median value of $42.0 million in 2023 and averaged $46.2 million.
  • Data for Foghorn Therapeutics' Shares Outstanding (Diluted Average) shows a peak YoY skyrocketed of 236.49% (in 2021) over the last 5 years.
  • Over the past 5 years, Foghorn Therapeutics' Shares Outstanding (Diluted Average) (Yearly) stood at $11.0 million in 2020, then soared by 236.49% to $37.2 million in 2021, then climbed by 11.89% to $41.6 million in 2022, then grew by 0.92% to $42.0 million in 2023, then surged by 30.79% to $54.9 million in 2024.